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Left ventricular activation-recovery interval variability predicts 1 
spontaneous ventricular tachyarrhythmia in heart failure patients. 2 
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ABSTRACT 21 
 22 
Background: Enhanced beat-to-beat variability of repolarization (BVR) is strongly linked to 23 
arrhythmogenesis and is largely due to variation in ventricular action potential duration (APD). 24 
Previous studies in humans have relied on QT interval measurements; however, a direct relationship 25 
between beat-to-beat variability of APD and arrhythmogenesis in humans has yet to be 26 
demonstrated. 27 
Objectives: This study aimed to explore the beat-to-beat repolarization dynamics within a heart 28 
failure population at the level of ventricular APD. 29 
Methods: 43 patients with heart failure and implanted cardiac resynchronization therapy 30 
defibrillator devices were studied. Activation-recovery intervals (ARI) as a surrogate for APD were 31 
recorded from the left ventricular epicardial lead while pacing from the right ventricular lead to 32 
maintain constant cycle length.  33 
Results: During mean follow-up of 23.6±13.6 months, 11 patients sustained VT/VF and received 34 
appropriate implantable cardioverter-defibrillator therapies (Anti-Tachycardia Pacing or shock 35 
therapy). ARI variability (ARIV) was significantly greater in patients with subsequent VT/VF vs. those 36 
without VT/VF (3.55±1.3 ms vs. 2.77±1.09 ms, p=0.047). Receiver operating characteristic curve 37 
analysis (AUC 0.71, p=0.046) suggested high and low risk ARIV groups for VT/VF. The Kaplan–Meier 38 
survival analysis demonstrated that the time until first appropriate therapy for VT/VF was 39 
significantly shorter in the high-risk ARIV group (p=0.028). ARIV was a predictor for VT/VF in the 40 
multivariate Cox model (HR, 1.623; 95% CI, 1.1 to 2.393; p=0.015). 41 
Conclusions: Increased left ventricular ARIV is associated with an increased risk of VT/VF in patients 42 
with heart failure.  43 
 44 
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INTRODUCTION 47 
 48 
Accurate prediction of individuals at risk of ventricular arrhythmia (VA) and sudden cardiac death 49 
remains a major challenge.
1
 Exaggerated beat-to-beat variability (BBV) of repolarization (BVR) is 50 
known to be associated with arrhythmogenesis in animal models
2-5
 and humans
6-11
 and has been 51 
proposed as a potential risk marker.  52 
 53 
The activation-recovery interval (ARI) is well validated.
12-14
 In vivo it can be obtained from pacing 54 
leads in ambulatory patients, invasively during electrophysiology studies, and more recently has 55 
been derived from non-invasive cardiac electrophysiology mapping techniques.
15
 As such it is readily 56 
available for the assessment of ventricular repolarization and therefor a potential adjunct in the 57 
prediction of patients at risk of VA. Recent animal studies have demonstrated significant increases in 58 
the BBV of ARI prior to the onset of Torsades de pointes and have highlighted its potential for 59 
integration into implantable cardiac devices to monitor arrhythmia risk.
16
  60 
 61 
In the present study, we have recorded left ventricular (LV) unipolar electrograms (UEGs), while 62 
pacing from the right ventricular (RV) lead to maintain a constant cycle length in patients with heart 63 
failure. From these electrograms we have calculated ARI variability (ARIV). We hypothesized that 64 
higher baseline ARIV would be seen in patients experiencing VA during follow-up.  65 
 66 
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METHODS 67 
 68 
Ethical Approval 69 
The study was approved by the local research ethics committee and conformed to the Declaration of 70 
Helsinki (latest revision: 64
th
 WMA General Assembly) standard. Informed consent was obtained in 71 
writing from all subjects. 72 
 73 
Study population and data acquisition 74 
We retrospectively analyzed the prospectively collected data of 43 consecutive patients who 75 
underwent electrogram recordings to study basic ARI within a heart failure population. The study 76 
enrolled patients with St. Jude Medical cardiac resynchronization therapy defibrillator (CRT-D) 77 
devices for primary or secondary indications of sudden cardiac death (SCD). Patients of either sex, 78 
>18 years of age and undergoing CRT-D follow-up at our institution were eligible. During a routine 79 
follow-up visit LV UEG recordings were made via the device programmer (Merlin, St. Jude Medical 80 
Inc., St Paul, MN). Effects of heart rate variability on repolarization dynamics were removed by 81 
establishing fixed cycle length with steady-state pacing (DDD-RV for sinus rhythm or VVI-RV for atrial 82 
fibrillation).
17
 A constant rate of 10 beats above the patient’s intrinsic heart rate was chosen with a 83 
minimum adaptation period of 2 minutes.
18
 A 30 second recording of LV UEG was made using the 84 
device programmer at a sampling frequency of 512 Hz and extracted for off-line analysis. 
19,20
 Figure 85 
1 shows examples of raw digital UEGs. Occurrence of VA therapy with either ATP or shock therapy 86 
was assessed by CRT-D checks and served as the endpoint. Programming of the CRT-D device was 87 
based on clinical evaluation of the attending electrophysiologist. CRT-D interrogation data of 88 
recorded events was evaluated by an electrophysiologist blinded to the outcome of the LV UEG data.  89 
 90 
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Repolarization variability analysis 91 
Raw digital LV UEG traces were analysed off-line using custom built MATLAB software (MathWorks 92 
Inc, Mass). Recordings were separately low pass filtered at both 80 and 30 Hz for calculation of 93 
activation times (ATs) and repolarization times (RTs), respectively. The choice of two separate 94 
frequencies for AT and RT calculation allowed us to maintain the sharp activation gradients required 95 
to identify ATs, whilst also successfully preserving the morphology of the slower T-wave to identify 96 
RTs. Consecutive ARIs were calculated by identifying AT and RT for each beat using the Wyatt 97 
method.
13,14,19,21,22
 Automated identification of ATs and RTs removed any observer variability. Figure 98 
1 shows examples of the identification of ATs and RTs and the resultant ARI across various 99 
morphologies of UEG. ARIV over the full 30s recording was then computed as. 100 
 = 	
∑ |	
 − 	|

	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)
 
where n beats is the number of beats contained within the 30s period.
23
  To account for the 101 
possibility that the magnitude of beat-to-beat changes may depend on the intrinsic ARI duration we 102 
introduced the ARIV index. The ARIV index provides a normalized value of the ARIV relative to the 103 
mean ARI duration for each patient. The ARIV index was computed as.  104 
	 !"# = 	

$%&'(
×
∑ |$%&)*+$%&)|
(,+
)-+
(	√.	×	)
     where    / =
∑ $%&)
(
)-+

 105 
 106 
 107 
 108 
Statistical Analysis 109 
Results are presented as mean±standard deviation for normally distributed variables and as median 110 
and interquartile range (IQR) for non-normally distributed variables. The independent-samples t-test 111 
was used to compare normally distributed continuous variables; otherwise the Mann-Whitney U test 112 
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was used. Categorical variables were compared using Fisher’s exact test. ROC analysis was 113 
performed using Youden’s index to determine the variable cut-off levels with optimal sensitivity and 114 
specificity for the endpoint. The estimated cutoff values were retrospectively used to reclassify and 115 
dichotomize the study subjects into high and low-risk categories. Kaplan-Meier survival analysis was 116 
used to address our hypothesis testing the association between increased ARIV and probability of 117 
first appropriate defibrillator therapy for VT/VF. Cox proportional hazards analyses were performed 118 
separately for each variable of interest (Mean ARI, ARIV and ARIV index). A P value of <0.05 was 119 
considered to be statistically significant for all tests. All statistical analyses were performed using 120 
SPSS (IBM Switzerland, Switzerland) and Prism (GraphPad Software Inc., California, USA).  121 
 122 
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RESULTS 123 
 124 
Data eligibility 125 
A total of 43 ambulatory heart failure patients underwent UEG recordings. Of these, 6 patients were 126 
excluded from the ARIV analysis: 2 due to a >15% ectopy burden during recordings, 3 due to 127 
significant electrogram fractionation (Figure 2A), 1 due to absence of a well-defined T-wave such 128 
that no positive gradient could be identified during repolarization (Figure 2B). ARIV analysis was 129 
performed in the remaining 37 patients. T-wave morphology remained constant and there were no 130 
AV conducted beats throughout the recordings. The median RV pacing rate used during LV UEG 131 
recordings was 85 bpm (IQR, 80 to 95). As expected, significant correlation was seen between the 132 
pacing rate and mean ARI (r=-0.725, p<0.001). However, there was no correlation between mean ARI 133 
and ARIV (r=0.045, p=0.792), nor the pacing rate and ARIV (r=-0.150, p=0.377).  134 
 135 
Study population  136 
Of those eligible for ARIV analysis (Table 1), 30 were men (81.1%) and 7 women (18.9%) who had 137 
undergone CRT-D implantation for primary (29 patients, 78.4%) or secondary (8 patients, 21.6%) 138 
prevention of SCD. The patients were enrolled in the study in median time 6.9 months after CRT-D 139 
implantation (range, 5.3 to 31.9 months). At the time of data acquisition, no patients had 140 
decompensated heart failure. All patients had electrolytes within ranges unexpected to disturb 141 
repolarization prior to UEG recordings (sodium 138.1±3.2 mEq/L, potassium 4.7±0.5 mEq/L). During 142 
follow-up no patients were initiated on class I or III antiarrhythmic agents, nor underwent coronary 143 
intervention/VT ablation prior to meeting the study endpoint or before conclusion of study follow-144 
up.  145 
                         146 
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Comparing patients with ischemic and non-ischemic cardiomyopathy, there was no difference in 147 
mean ARI (257.69±26.6 ms vs. 251.21±35.27 ms, p=0.554), ARIV (3.44±1.32 ms vs. 2.67±0.98 ms, 148 
p=0.055), nor the ARIV index (1.37±0.6% vs. 1.07±0.36%, p=0.115). LV ejection fraction (LVEF) 149 
showed no correlation with mean ARI (rs=0.021, p=0.901), ARIV (rs=0.020, p=0.907) nor the ARIV 150 
index (rs=0.039, p=0.818). Between patients with primary and secondary prevention indications for 151 
CRT-D there was no difference in mean ARI (257.34±32.35 ms vs. 241.97±26.99 ms, p=0.207). 152 
Differences in ARIV approached significance (2.83±1.21 ms vs. 3.62±0.94 ms, p=0.051), and a 153 
significantly higher ARIV index was seen in the secondary prevention group (1.12±0.5% vs. 154 
1.49±0.34%, p=0.021). 23 of the patients were CRT responders and 14 non-responders (a CRT 155 
responder was defined as a ≥5% improvement in LVEF from pre-implant). Between responders and 156 
non-responders there was no observed difference in mean ARI (253.26±35.24 ms vs. 255.26±25.61 157 
ms, p=0.865), ARIV (2.94±1.14 ms vs. 3.11±1.3 ms, p=0.699) nor ARIV index (1.18±0.48% vs. 158 
1.23±0.53%, p=0.817). 159 
 160 
Implantable cardioverter-defibrillator therapy  161 
Following LV UEG recordings a mean follow-up of 23.6±13.6 months took place. During follow-up 11 162 
patients of 37 reached the endpoint of appropriate ICD therapy for VT/VF. ATP was attempted and 163 
successful in 9 patients with VT. One patient with VT had successful rescue shock therapy. One 164 
patient experienced VF with successful shock therapy. One patient died from heart failure before 165 
reaching the endpoint. Table 1 shows a comparison of clinical characteristic of patients with and 166 
without subsequent appropriate ICD therapy for VT/VF.  167 
 168 
ARIV was significantly greater in patients with subsequent VT/VF events vs. those without VT/VF 169 
events (3.55±1.3 ms vs. 2.77±1.09 ms, p=0.047). The ARIV index was also significantly greater in 170 
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patients with subsequent VT/VF events vs. those without VT/VF events (1.43±0.5% vs. 1.1±0.47%, 171 
p=0.036). No observed difference between groups was found in mean ARI (249.34±27.91% vs. 172 
256±33.31%, p=0.618).  Receiver operating characteristic (ROC) curve analysis (Figure 3) suggested 173 
cut-off levels for ARIV of ≥2.52 ms with 82% sensitivity (95% CI, 48-98%) and 58% specificity (95% CI, 174 
37-77%) (AUC 0.71; 95% CI, 0.53-0.89; p=0.046) and ARIV index of ≥1.14% with 64% sensitivity (95% 175 
CI, 31-89%) and 65% specificity (95% CI, 44-83%) (AUC 0.72; 95% CI, 0.55-0.9; p=0.036) to 176 
dichotomize into high/low risk for the endpoint of appropriate ICD therapy.  177 
 178 
Table 2 shows the clinical characteristics of patients with ARIV dichotomized at high and low risk of 179 
VT/VF.  When comparing subjects in the high-risk group for ARIV, 45% experienced an episode of 180 
VT/VF by 3 years, compared with 11.8% in the low-risk group. Figure 4A demonstrates the 181 
separation of the Kaplan-Meier curves at the variable cut-off for ARIV (Mantel-Cox log-rank test, 182 
p=0.028). When comparing subjects in the high-risk group for ARIV index, 43.8% experienced an 183 
episode of VT/VF by 3 years, compared with 19.0% in the low-risk group. Figure 4B demonstrates 184 
the separation of the Kaplan-Meier curves at the variable cut-off for ARIV index (Mantel-Cox log-rank 185 
test, p=0.079). 186 
 187 
Mean ARI, ARIV and the ARIV index were tested separately in the multivariate Cox proportional-188 
hazards regression model for all VT/VF events, with the significant clinical covariate LVEF. Low LVEF 189 
remained a significant predictor of appropriate ICD therapy for VT/VF in all models tested. Mean ARI 190 
was not predictive (HR, 0.997; 95% CI, 0.977-1.017; p=0.758). ARIV (HR, 1.623; 95% CI, 1.1-2.393; 191 
p=0.015) and the ARIV index (HR, 3.256; 95% CI, 1.222-8.676; p=0.018) were independent predictors 192 
of VT/VF (Figure 5). After exclusion of patients with secondary indications for ICD therapy both ARIV 193 
(HR, 1.518; 95% CI, 1.009-2.285; p=0.045) and the ARIV index (HR, 2.87; 95% CI, 1.033-7.975; 194 
p=0.043) remained independent predictors of VT/VF. After exclusion of patients on amiodarone both 195 
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ARIV (HR, 1.625; 95% CI, 1.114-2.371; p=0.012) and the ARIV index (HR, 3.259; 95% CI, 1.262-8.411; 196 
p=0.015) remained independent predictors of VT/VF. 197 
 198 
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DISCUSSION 199 
 200 
To our knowledge, this is the first study to demonstrate an association between VA risk and 201 
increased LV BVR. The main findings were: 1) increased ARIV was associated with an independent 202 
risk for VT/VF; 2) increased ARIV index (ARIV normalized to mean ARI) remained an independent 203 
predictor for VT/VF; 3) there was no association between mean ARI and VT/VF risk. 204 
 205 
Relation to prior work on repolarization variability  206 
The potential for stratification of individuals at risk of VA by means of repolarization instability has 207 
been demonstrated with QT intervals from the surface ECG and RV intracardiac electrograms. 
6-11
 208 
Our findings of higher values of BBV of ARI in heart failure patients experiencing VT/VF extends 209 
these observations to the level of the ventricular APD and to the assessment of LV BVR. The ROC 210 
analysis found ARIV to be more sensitive than the ARIV index in the prediction of ICD therapies. This 211 
was highlighted again in the Kaplan-Meier analysis showing less separation in the curves for ARIV 212 
index when compared to ARIV. These results would suggest that use of BBV of ARI to assess risk of 213 
VT/VF is more reliable without adjustment for basic ARI.  214 
 215 
A major component of QTV is heart rate variability and both the QT interval and APD are strongly 216 
cycle length dependent 
24,25
. As the majority of QTV studies occurred in the absence of controlled 217 
cycle length it is technically challenging to separate heart rate driven QTV from actual fluctuations in 218 
the QT interval.  RV pacing to obtain cycle length control as employed in our study removes the 219 
component of BVR due to heart rate variability. 220 
 221 
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It is accepted that the QT interval in a given ECG lead measures the interval between the earliest 222 
depolarization and latest repolarization as projected onto the axis of that lead.
26
 Given its spatial 223 
heterogeneity the use of multi-lead ECG recordings to assess QTV has been suggested but warrants 224 
further investigation.
26
 The in vivo dispersion of ARIV and correlations to various body surface ECG 225 
repolarization indices should be studied and could be invaluable in our understanding of both QTV 226 
and ARIV.   227 
 228 
Relation to prior work on basic APD and QT interval measurements 229 
In the present study, basic ARI in heart failure patients was not predictive of VT/VF events. This is 230 
consistent with several studies reporting QT variability as a stronger predictor of arrhythmia than QT 231 
prolongation. 
2,3,5,7,8
 These findings pointing to instability of repolarization as a key factor would be in 232 
keeping with a cellular mechanism such as proposed by Johnson et al
27
, who also observed 233 
dissociation between APD variability and basic APD under certain conditions. 234 
 235 
Shortening of basic APD occurs in responders to CRT, whilst lengthening of basic APD occurs in non-236 
responders. 
20
 In vivo electrical remodelling in heart failure at the level of BBV-APD needs to be 237 
studied prospectively and may offer insight into the impact of CRT on VAs. 238 
 239 
Mechanisms of beat-to-beat variability of repolarization 240 
Several mechanisms have been proposed for the cellular basis of BBV-APD. Its apparently random 241 
nature suggests the involvement of a stochastic process. Stochastic variation of fast sodium current 242 
(INa), L-type calcium current (ICaL), transient outward current (Ito), rapid delayed rectifier (Ikr) and slow 243 
delayed rectifier (Iks) potassium currents has been shown to influence BBV-APD
23,28,29
 with 244 
considerable interdependence between individual channels.
23
 Spontaneous calcium release from the 245 
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sarcoplasmic reticulum exhibits BBV and in the presence of calcium overload has been shown 246 
experimentally and in silico to generate BBV-APD.
27
 This mechanism was due to spontaneous 247 
calcium release from the sarcoplasmic reticulum in late diastole reducing the subsequent calcium 248 
transient and hence reducing ICaL deactivation and prolonging the APD. However, the extent to which 249 
these effects seen in isolated cells may be operative in the whole heart where cells are well coupled 250 
is uncertain due to electrotonic interaction between cells.
30
 Nevertheless under conditions of 251 
calcium overload or reduced repolarization reserve, the effect of stochasticity on channel behavior 252 
may be enhanced suggesting that these effects may become operative in pathological conditions. 253 
BBV-APD may be arrhythmogenic either by the development of early or delayed 254 
afterdepolarizations
27
 or by enhanced dispersion of repolarization facilitating re-entry.  255 
 256 
Clinical implications and future work 257 
Risk stratification of patients at high risk of sudden cardiac death remains a major challenge. In view 258 
of the multiple mechanisms involved it is unlikely that a single test would prove sufficient and that a 259 
combination of clinical characteristics with a selection of stratification tools may be more 260 
appropriate.
31
 In this context, our study builds on the body of evidence highlighting the potential for 261 
assessment of baseline BVR to form part of the risk stratification tool. 262 
 263 
Wijers et al
16
 have highlighted the significance of the temporal behavior of ARI prior to the onset of 264 
VA in dogs. Furthermore, this work demonstrated comparable short-term variability of ARI between 265 
RV and LV. The potential for automated continuous real-time monitoring of ARIV offers a novel 266 
future application for ICDs. However, the optimal recording location is unknown and further work is 267 
needed to compare ARIV across multiple simultaneous recording sites within the heart. Paroxysmal 268 
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atrial arrhythmias may result in variable ventricular filling in BiV paced patients and as such their 269 
influence on the ventricular ARI within a CRT population should be studied. 270 
 271 
Limitations 272 
The study population was relatively small and as a single tertiary centre study the patient group may 273 
not be representative of the usual CRT-D population. These results should be validated in a larger 274 
multicenter prospective study of a primary prevention ICD indication cohort. As ischemia testing was 275 
not conducted as part of the protocol we are unable to determine the influence of ischemia on BBV 276 
of ARI. Our observations are confined to a single LV epicardial site. Regional variation of the 277 
electrophysiological properties throughout the ventricular myocardium makes it possible that other 278 
regions may have demonstrated differing results. Short and long-term variation in ARIV should be 279 
studied in order to determine the optimal duration and frequency of recordings for its use as a 280 
predictor of VA.
32
 Whilst strategies to analyze fractionated electrograms have been proposed,
33
 a 281 
clear consensus in their interpretation does not exist. In the context of the assessment of BVR this 282 
could prove a challenge.  Furthermore, the presence of a high ectopy burden or the lack of a 283 
gradient to define repolarization time could exclude some patients altogether. In our study 14.0% of 284 
patients were excluded due to these limitations thus highlighting an area for future work.  285 
 286 
Conclusion 287 
In patients with heart failure, increased ARIV is associated with increased risk of spontaneous VT/VF. 288 
These results accord with observations in QTV and extend observations to assessment of left 289 
ventricular BVR and specifically to the level of ventricular APD. Our findings are supportive of the 290 
possible utility of BVR as an adjunct to risk stratification of patients at risk of ventricular arrhythmia.  291 
 292 
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Table 1. Baseline characteristics of patients with and without subsequent appropriate ICD therapy 411 
for VT/VF. NYHA, New York Heart Association. 412 
Variables No VT/VF event 
(n=26) 
VT/VF events at 
follow-up 
(n=11) 
P value 
Age (IQR), years 68 (63-77) 63 (52-66.5) 0.059 
Male, n (%) 19 (73.1) 11 (100) 0.080 
Ischemic cardiomyopathy, n (%) 12 (46.2) 4 (36.4) 0.723 
Ejection fraction ±SD, % 38.9 ± 11.7 26 ± 11.2 0.004 
NYHA class ≥ 2, n (%) 16 (61.5) 9 (81.8) 0.279 
Secondary prevention ICD, n (%) 6 (23.1) 2 (18.2) 1 
Diabetes mellitus, n (%) 8 (30.8) 4 (36.4) 1 
Hypertension, n (%) 8 (30.8) 5 (45.5) 0.465 
Atrial fibrillation, n (%) 6 (23.1) 4 (36.4) 0.442 
Beta-blockade, n (%) 21 (80.8) 11 (100) 0.295 
ACE inhibitor, n (%) 24 (92.3) 11 (100) 1 
Aldosterone antagonists, n (%) 15 (57.7) 4 (36.4) 0.295 
Digoxin, n (%) 4 (15.4) 3 (27.3) 0.403 
Amiodarone, n (%) 3 (11.5) 0 (0) 0.540 
Biventricular pacing percentage (IQR), % 99 (97-99) 98 (94-99) 0.377 
Pacing rate for EGM recording (IQR), bpm 80 (80-95) 90 (82.5-92.5) 0.780 
 413 
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Table 2. Clinical characteristics of patients with ARIV dichotomized as per ROC suggested optimal 414 
cut-off values. NYHA, New York Heart Association.  415 
Variables ARIV low-risk 
(n=17) 
ARIV high-risk 
(n=20) 
P value 
Age (IQR), years 68 (62-76) 66 (56-75) 0.279 
Male, n (%) 12 (70.6) 18 (90) 0.212 
Ischemic cardiomyopathy, n (%) 5 (29.4) 11 (55) 0.185 
Ejection fraction ±SD, % 35.5 ± 13.6 34.8 ± 12.5 0.857 
NYHA class ≥ 2, n (%) 10 (58.8) 15 (75) 0.482 
Secondary prevention ICD, n (%) 1 (5.9) 7 (35) 0.048 
Diabetes mellitus, n (%) 7 (41.2) 5 (25) 0.482 
Hypertension, n (%) 2 (11.8) 11 (55) 0.014 
Atrial fibrillation, n (%) 6 (35.3) 4 (20) 0.460 
Beta-blockade, n (%) 14 (82.4) 18 (90) 0.644 
ACE inhibitor, n (%) 16 (94.1) 19 (95) 1 
Aldosterone antagonists, n (%) 11 (64.7) 8 (40) 0.191 
Digoxin, n (%) 5 (29.4) 2 (10) 0.212 
Amiodarone, n (%) 0 (0) 3 (15) 0.234 
Biventricular pacing percentage ±SD, % 99 (98-99) 98 (94-99) 0.368 
Pacing rate for EGM recording ±SD, bpm 90 (80-100) 80 (80-90) 0.148 
 416 
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Figure 1. Unipolar electrograms recorded from the left ventricular lead of 3 separate patients 417 
demonstrating local activation (star) and repolarization (square).  418 
419 
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Figure 2. Two pitfalls of ARIV analysis: (A) fractionation, (B) neutral gradient during repolarization.  420 
 421 
422 
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Figure 3. Receiver operating characteristic analysis for (A) ARIV and (B) ARIV index to predict VT/VF. 423 
Optimal cut-off levels determined by Youden’s index.  424 
 425 
 426 
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 427 
Figure 4. Kaplan-Meier curves for freedom from VT/VF events in patients dichotomized by ROC 428 
derived optimal cut-off values for (A) ARIV and (B) ARIV index. 429 
 430 
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Figure 5. Hazard ratios (adjusted for LVEF) for the association of mean ARI, ARIV and ARIV index with 431 
appropriate ICD therapy for VT/VF. 432 
 433 
 434 
 435 
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